Wednesday 26 July 2017 | The one stop source for free breaking news, expert analysis, and videos on AIM and LSE listed shares
Alliance Pharma (APH) has updated on trading for the first half of 2017, ahead of a results announcement expected on 13th September…
Alliance Pharma (APH) has made an AGM update announcement, including that trading “is good and in line with the board's expectations” and that “cash flow in the business remains strong”. This is a healthy reaffirmation of our BUY tip of last month which is now well in the money.
Specialty pharmaceutical company, Alliance Pharma (APH) is a previous successful share tip for us - recommended at 31p, with gains banked at 43p in 2015. However, there has since been positive development which looks inadequately reflected in a current sub 50p offer price and, noting also the continued presence of famed investors Nigel Wray and Slater Investments as major shareholders…
In this video from the storming success that was the 2017 UK Investor Show, John Dawson, CEO of Alliance Pharma (APH), is at the podium. And make sure that you keep April 21 2018 free for next year's UK Investor Show.
Alliance Pharma (APH) has, relatively, recently completed a transformational acquisition. I know that Nigel Wray remains a big fan as does Mark Slater. Sensible value investors should thus find the presentation by John Dawson of interest
Hello Share Trekkies. The health game is a good place to be for winning share seekers like us in 2016. Bio-science firms are set to reap the benefit of an ageing world population with all its attendant health problems. And even younger folk will sadly require more medical care, unless they can do something about their unhealthy diets.
Alliance Pharma (APH) has updated investors that “trading in the first four months of 2015 has been satisfactory” and that“we look forward to the remainder of 2015 with confidence.”
Speciality pharmaceuticals company Alliance Pharma (APH) has announced results for the 2014 calendar year and that “we enter 2015 well placed for resumed growth”. That is not discounted in the current share price.
Speciality pharmaceutical company, Alliance Pharma (APH) has updated that 2014 “pre-tax profits are expected to be in line with current market expectations” on turnover of £43.5 million and that “we continue to evaluate a number of acquisition opportunities”.
Alliance Pharma (APH) last week announced results for the first half of the 2014 calendar year and that “we expect full year results to be in line with market expectations”. This makes the shares a buy at up to 35p
Alliance Pharma (APH) has updated investors attending its AGM that “trading in the first four months of 2014 has been in line with expectations” and that “we continue to work towards delivering further earnings enhancing acquisitions to outperform those plans”.
Direct from the Queen Elizabeth Conference Centre a video featuring a UK Investor Show 2014 presentation by John Dawson of Alliance Pharma (APH)
Alliance Pharma (APH) has announced that Nigel Wray has purchased a further 1.55 million shares in the company, taking his shareholding to 39,656,995 shares, 15.02% of the company's issued share capital.
Speciality pharmaceutical company, Alliance Pharma (APH) last week announced that “turnover for 2013 is expected to be £45.5m (2012: £44.9m) and pre-tax profits are expected to be in line with current market expectations” (expectations are for earnings per share of around 3.5p) as well as an acquisition of the rights to the thyroid product Irenat in Germany from subsidiaries of Bayer AG.
Shares in speciality pharmaceutical company Alliance Pharma (APH) trade at 35.25p-35.75p on the back of its results announcement for the first half of calendar 2013 which came out last week. Having been added to the Recovery portfolio on my Nifty Fifty website at a 31p offer price in December, we are ahead but not by as much as I would have hoped.
AIM-listed speciality pharmaceutical company Alliance Pharma (APH) has announced “trading in the first half of the year has been in line with management’s expectations” and that it “continues to explore a number of acquisition opportunities and remains confident of the outlook for the full year”. So is it a buy. Pushed for an answer I’d say yes.
Alliance Pharma (APH) is in the news today as it has announced an $11.5 million (£7.5 million) acquisition of all existing rights to the ‘Syntometrine’ drug from industry major Novartis
Specialty pharmaceutical company Alliance Pharma (APH) has today announced an $11.5 million (£7.5 million) acquisition of all existing rights to the ‘Syntometrine’ drug from industry major Novartis. This is part of its strategy of buying in “orphan” brands from majors which it can then monetize by flogging through its existing sales infrastructure.
AIM-listed speciality pharmaceutical company Alliance Pharma (APH) has updated that “trading in the first four months of 2013 has been 6% ahead of the same period last year (5% on an underlying basis), with turnover of £15.1 million”.
A new stock, of which star fund manager Mark Slater is a fan, has just been added to the Growth Portfolio on the 'Nifty Fifty' website which I write with Tom Winnifrith.
Alliance Pharma (APH), the speciality pharmaceutical company which acquires and licenses established products in niche areas, announced its calendar 2012 results a couple of weeks ago. The numbers contained no nasty shocks. That is no surprise, one of the great attractions of Alliance is that there is a real visibility of revenues. I tipped the shares on my premium Nifty Fifty service at 31p (offer price) in December and they now trade at 36-37p but are still a buy.